Ingredient Studies Do Not Substantiate Your Formula

What did the court hold in FTC v. Wellness Support Network?

A federal court granted the FTC summary judgment on February 19, 2014, in FTC v. Wellness Support Network, Inc., No. 3:10-cv-04879 (N.D. Cal.), over unsubstantiated diabetes claims for a dietary supplement. We pulled the underlying order and confirmed the date and docket number ourselves before writing this. The court didn't just find the ads deceptive — it endorsed a specific evidentiary standard for what proof would have had to look like.

FTC's own Health Products Compliance Guidance later cited that ruling in footnote 45 for a principle that runs through this entire vertical: trials substantiating a formula's effect need to test the formula, not its parts, because, in the guidance's own words describing the court's reasoning, 'there may be interactions between the ingredients that affect their physiological actions.' That's the whole case in one clause.

Ingredient science and formula science are not interchangeable evidence.

Why do ingredient interactions defeat a stacked evidence file?

Ingredient interactions defeat a stacked file because combining compounds can change how each one is absorbed, metabolized and cleared, and no single-ingredient trial measures that. Bioavailability, the dose fraction actually absorbed, shifts when compounds compete for the same transport or enzyme pathway — sometimes up, sometimes down, and rarely in the direction a marketing team predicted.

A nine-ingredient proprietary blend, ingredients combined at an undisclosed dose, advertised as 'clinically backed' by nine citations is, legally, backed by nothing at all, because none of those nine trials tested what happens when the nine compounds are dosed together. A similar failure sank a probiotic brand whose entire proof was its own bibliography, not a formula-level trial. We checked how courts have treated this exact defense and found the Wellness Support Network holding is the clearest statement of it on record — not a guideline, a summary-judgment ruling.

What does 'same dosage and formulation' require in practice?

In practice it requires the trial to test the exact SKU sold — same excipients, same delivery format, same ratios — not a close relative of it. A capsule formula tested at one dose and then reformulated into a gummy, or bumped up on overage to survive shelf life, is no longer the product the trial covered.

Manufacturers routinely build in nutrient overages of 3% to 25%, and higher for probiotics, so the label claim still holds true on the day the product expires rather than the day it ships. Every overage adjustment is a formulation change. If a supplier tweaks a ratio between batches to hit a stability target, the trial cited on the sales page was run on a formula that technically no longer exists — a detail almost no advertorial discloses, and one worth understanding before you scale a custom formulation.

How many nutra offers could actually meet this standard?

Very few, and the honest answer is that nobody publishes the number. A formula-level randomized trial on a finished supplement routinely runs into six figures before a single bottle ships, and the citations that stand in for it usually sit on the ingredient tab, where most reviewers never separate a compound's own trial from the finished formula's.

Consider what a compliant trial stacks on top of an already expensive supply chain: a custom formulation alone carries setup costs of $2,000 to $15,000 for development and $3,000 to $8,000 for stability testing before a single dose reaches a person, and that's before paying for the clinical site, the placebo arm, the statistician and the IRB review a real RCT (a randomized, placebo-controlled trial) requires. Compare that to a nine-ingredient proprietary blend built entirely from citations to other companies' published research on the individual compounds — a route that costs nothing beyond the hours it takes to build a reference list, which is exactly why it's the default in this vertical and exactly why the court in Wellness Support Network rejected it as proof of anything about the finished product.

Does a proprietary blend make the problem worse?

Yes, because a proprietary blend hides the one number a buyer would need to check whether any cited study even applies. Under 21 CFR 101.36, a proprietary blend must disclose its total combined weight and list ingredients in descending order by weight — but not the milligram dose of each individual ingredient inside it.

That gap matters directly against the Wellness Support Network standard, because 'same dosage' is unverifiable when the dosage itself is legally hidden. A buyer reading a proprietary-blend label can't confirm whether a 500 mg total blend contains a clinically studied 300 mg of the active compound or a token 20 mg dusted in for the ingredient list — and neither can you, unless the seller hands over a batch record no proprietary-blend brand is required to share. The same opacity is a cousin of a different problem: when an ingredient becomes the drug claim instead of just an unverifiable dose.

How does this interact with the totality-of-evidence rule?

It compounds the problem, because FTC doesn't count studies — it weighs them, and a single well-designed null result can outweigh two positive ones. In the guidance's own Example 30, an advertiser held two controlled, double-blind studies showing a modest six-week fat-loss effect against one equally well-controlled 12-week study that found no significant difference, and FTC concluded, 'given the totality of the evidence, the claim is unsubstantiated.'

More citations do not mean more proof.

The same logic reaches endpoint mismatches, not just conflicting results. FTC's guidance separately notes, citing a federal court's reasoning, that 'a study examining metabolic endpoints cannot determine whether weight loss will also occur' — the same principle applied to a different pairing of variables: the outcome measured in a study has to match the outcome claimed on the page, or the study doesn't count toward the claim at all.

What should a buyer request as a substantiation file before promoting?

Ask for the trial itself, not the ingredient list it's built from — specifically, a study run on the exact SKU, at the exact dose, in the exact delivery format you'll be advertising. Everything short of that is a citation, not a substantiation file, and the difference is the one the Wellness Support Network court drew.

We could not verify what share of currently promoted nutra offers have ever run a trial on their own finished formula — no public registry tracks that field, and settling it precisely would take a manual audit cross-referencing clinical trial registrations against product SKUs, which is outside what we did here. What we can state is the standard itself: per FTC's own guidance, 'substantiation of health-related benefits will need to be in the form of randomized, controlled human clinical testing.'

• The finished-product trial, or written confirmation none exists — not ingredient-level studies alone
• The exact dose tested against the exact dose in the SKU being promoted
• Whether the study population and endpoint match the claim in the ad, not an adjacent one
• Confirmation of what's inside any proprietary blend, in writing, beyond the label's descending-weight order
• A copy of what [the substantiation file](/niches/the-substantiation-file-building-the-folder-you-hope-nobody-asks-for) actually contains before a dollar of traffic runs

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For external context, readers should compare advertising and research decisions against authoritative primary references such as FTC health claims guidance, Meta advertising standards, and Meta Ad Library. Daily Intel adds the proprietary direct-response layer: blackhat, greyhat, and whitehat campaign pattern comparison across VSL-heavy niches and 14+ language markets.

For deeper evaluation, continue through Nutra niche intelligence directory, Cortisol Supplement Ads: The Stress-Belly Angle Wave, Offers Targeting GLP-1 Users: The Side-Effect Economy, Best Nutra Affiliate Networks: Ranked by Offer Depth, Probiotic Weight Loss Offers: The Gut-Slim Ad Angle, and GLP-1 affiliate marketing intelligence. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.